BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
May 14, 2024 16:05 ET
|
BioAtla, Inc.
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for...
BioAtla to Participate in the Citizens JMP Life Sciences Conference
May 08, 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
May 07, 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
May 06, 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 16:35 ET
|
BioAtla, Inc.
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
March 26, 2024 16:01 ET
|
BioAtla, Inc.
CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination...
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
March 19, 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 07, 2024 08:00 ET
|
BioAtla, Inc.
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical activity for CAB anti-Nectin4-antibody drug...
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
December 13, 2023 08:00 ET
|
BioAtla, Inc.
Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and...